A new treatment for Covid-19, developed by Celltrion, a company in South Korea, is undergoing ‘rapid evaluation’ by EMA – the European Medicines Agency – with a view to approval for use across the bloc. ‘Regdanvimab’ uses a monoclonal antibody which reportedly attaches itself to the ‘spike’ protein of SARS-CoV-2 which causes Covid-19 to develop in certain infected people. The result is a reduced capacity of the virus to enter patients’ cells. Explain reports, EMA’s hope is that this new medication can be given to patients with moderate
New medication promising to avoid hospitalisations under ‘rapid evaluation’ by EMA
